Turbica I, Posner M, Bruck C, Barin F
Département de Microbiologie Médicale et Moléculaire, Unité de Recherche Associée Centre National de la Recherche Scientifique 1334, Centre Hospitalier Universitaire Bretonneau, Tours, France.
J Clin Microbiol. 1995 Dec;33(12):3319-23. doi: 10.1128/jcm.33.12.3319-3323.1995.
We report the development of an immunoassay for the titration of antibody to the CD4-binding site (CD4BS) of the human immunodeficiency virus type 1 (HIV-1) surface glycoprotein gp120. This assay is a competitive enzyme-linked immunosorbent assay in which serum antibodies compete with labeled F105, a human monoclonal antibody whose corresponding epitope overlaps the conformation-dependent CD4BS, for binding to purified recombinant gp120 coated on a solid phase. Ninety-nine percent (109 of 110) of HIV-1-positive French patients and 91% (51 of 56) of HIV-1-positive African patients had CD4BS antibodies, indicating that the conformational CD4BS epitope is well conserved among different subtypes of HIV-1. Titers of CD4BS antibodies according to clinical status appeared to be not statistically different. A longitudinal study in 21 seroconverters showed that, for the majority of individuals, CD4BS antibodies appeared early and persisted at relatively high titers for several years. None of 21 HIV-2-seropositive patients had CD4BS antibodies in our assay, suggesting that the antibodies produced during HIV-2 infection are not cross-reactive with the CD4BS of HIV-1 gp120.
我们报告了一种用于滴定针对人类免疫缺陷病毒1型（HIV-1）表面糖蛋白gp120的CD4结合位点（CD4BS）抗体的免疫测定方法的开发。该测定是一种竞争性酶联免疫吸附测定，其中血清抗体与标记的F105竞争，F105是一种人单克隆抗体，其相应表位与构象依赖性CD4BS重叠，用于结合包被在固相上的纯化重组gp120。99%（110例中的109例）的HIV-1阳性法国患者和91%（56例中的51例）的HIV-1阳性非洲患者具有CD4BS抗体，表明构象性CD4BS表位在HIV-1的不同亚型中高度保守。根据临床状态的CD4BS抗体滴度似乎无统计学差异。对21例血清转化者的纵向研究表明，对于大多数个体，CD4BS抗体出现较早，并在相对较高滴度下持续数年。在我们的测定中，21例HIV-2血清阳性患者均无CD4BS抗体，这表明HIV-2感染期间产生的抗体与HIV-1 gp120的CD4BS无交叉反应。
